Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 12 of 20 for:    "Lens Disease" | "Estradiol"

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery (CIMPLIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04205916
Recruitment Status : Recruiting
First Posted : December 20, 2019
Last Update Posted : December 20, 2019
Sponsor:
Collaborator:
Ocular Therapeutix, Inc.
Information provided by (Responsible Party):
Ophthalmic Consultants of Long Island

Brief Summary:
To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.

Condition or disease Intervention/treatment Phase
Patient Preference Drug: Dexamethasone Other: Standard of care surgery Phase 4

Detailed Description:

This is a randomized, self-controlled prospective clinical study. On initial consultation within one month of scheduled cataract surgery, each study subject will be randomized by a random number generator to receive one of two treatment groups, either experimental or control in the first eye. The second eye will undergo cataract surgery 2 weeks later and will be treated with the other treatment group:

Experimental Group: A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.

Control Group: A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Patients undergoing bilateral cataract Surgery
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Prospective Trial Evaluating a Intracanalicular Insert Delivery System Compared to Traditional Topical Drops in Controlling Post-operative Pain and inFlammation in Subjects Undergoing Sequential Bilateral Cataract Surgery
Actual Study Start Date : November 4, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Experimental Group
A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
Drug: Dexamethasone
Drugs to be administer during cataract surgery to experimental group
Other Names:
  • Ketorolac
  • moxifloxacin

Active Comparator: Control Group
A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
Other: Standard of care surgery
Standard method used for surgery and the use of post operative drops




Primary Outcome Measures :
  1. Patient Preference [ Time Frame: Day 28 of second eye surgery ]
    Patient preference for medication protocol between the two eyes as assessed by using a standard set of questions


Secondary Outcome Measures :
  1. Summed Ocular Inflamation Score [ Time Frame: Day 14 each eye ]
    Sum of the mean anterior chamber cells and anterior flare score as measured by Slit Lamp Biomicroscopy

  2. Surgical care [ Time Frame: Day 28 of second eye surgery ]
    Patient assessment of surgical care quality as measured by the CAHPS survey

  3. Post-operative pain [ Time Frame: Day 7 each eye ]
    Absence of post-operative ocular pain as measured by ocular pain assessment numerical grading scale 0-10

  4. Best Corrected Visual Acuity (BCVA) [ Time Frame: 2 month / 60 days Visit for second eye ]
    Mean change in BCVA from baseline

  5. Distance Visual Acuity (VA) [ Time Frame: 2 month / 60 days Visit for second eye ]
    Mean change in Distance VA

  6. Physician evaluation of insertion [ Time Frame: Post-op Day 1 for experimental group ]
    Physician ease of intracanalicular insertion evaluation as measured by physician questionnaire

  7. Adverse Events [ Time Frame: 2 month / 60 days Visit for second eye ]
    Incidence and severity of ocular and systemic Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A male or female subject in good general health (as determined by the Investigator), > 22 years of age at the time of the screening visit
  • A subject must be willing and able to sign informed consent
  • A woman of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control. Acceptable methods of birth control include intrauterine device (IUD), oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; and barrier methods with spermicide.
  • A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits
  • A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned

Exclusion Criteria:

  • A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
  • A subject with structural lid abnormalities (e.g., ectropion, entropion) in their schedule surgical eye
  • A subject with a puncta >0.9 mm prior to dilation in their scheduled surgical eye
  • A subject experiencing significant ocular pain or discomfort in either eye at the screening visit or on the day the plug is to be inserted
  • A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit
  • A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit
  • A subject with a known sensitivity to any of the study medications; A subject with a known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article
  • A subject with a history as a steroid responder
  • A subject with capsule or zonular abnormalities with preoperative lens tilt and/or decentration (e.g., Marfan's syndrome), or may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome)
  • A subject has a history of ocular trauma in their scheduled surgical eye
  • A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening
  • A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) in their scheduled surgical eye.
  • A subject with a corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) in their scheduled surgical eye
  • A subject with evidence of keratoconus or significant irregular astigmatism on pre-operative topography in their scheduled surgical eye
  • A subject with evidence of Epithelial Basement Membrane Dystrophy on slit-lamp exam
  • A subject that has been wearing Poly Methyl Metharcylate (PMMA) lenses within 6 months, gas permeable lenses within one month, or extended-wear or daily soft contact lens within 7 days of their scheduled surgery
  • A subject with an inability to achieve keratometric stability for contact lens wearers
  • A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye
  • A subject with uncontrolled glaucoma
  • A subject that requires an Limbal Relaxing Incision (LRI) or AI procedure before, during or after cataract surgery
  • A subject that may or is expected to undergo surgical intervention and/or ocular laser treatment prior to or during the study period
  • A subject that requires the use of systemic or ophthalmic Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid medications during the study period.
  • A subject that requires the use of system or ocular medications that may affect vision, ocular inflammation or pain
  • A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., autoimmune disease, connective tissue disease, immunocompromised, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.)
  • A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
  • A subject with diabetes that is poorly controlled
  • A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.

Intra-Operative Exclusion Criteria (Surgical Complications):

  • Sulcus-sulcus or bag-sulcus fixation
  • Posterior capsular rupture or zonular dialysis
  • Disruption of anterior hyaloids face
  • Vitreous loss
  • Capsulorhexis tear
  • Floppy iris syndrome
  • Requirement for the use of trypan blue, capsular tension ring or other intraocular device other than the Intra ocular lens (IOL)
  • Inability to place IOL in capsular bag
  • Significant anterior chamber hyphema
  • Zonular rupture.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04205916


Contacts
Layout table for location contacts
Contact: Erin Loweree 516-593-4026 eloweree@ocli.net
Contact: Isabel Lezcano 516-593-4026 ilezcano@ocli.net

Locations
Layout table for location information
United States, New York
Ophthalmic Consultants of Long Island Recruiting
Garden City, New York, United States, 11530
Contact: Erin Loweree    516-593-4026    eloweree@ocli.net   
Contact: Isabel Lezcano    516-593-4026    ilezcano@ocli.net   
Principal Investigator: Eric Donnenfeld         
Sponsors and Collaborators
Ophthalmic Consultants of Long Island
Ocular Therapeutix, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Eric Donnenfeld, MD Physician

Layout table for additonal information
Responsible Party: Ophthalmic Consultants of Long Island
ClinicalTrials.gov Identifier: NCT04205916    
Other Study ID Numbers: CIMPLIFY
First Posted: December 20, 2019    Key Record Dates
Last Update Posted: December 20, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Norgestimate, ethinyl estradiol drug combination
Cataract
Eye Diseases
Moxifloxacin
Dexamethasone
Dexamethasone acetate
Ketorolac
Ketorolac Tromethamine
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Contraceptives, Oral, Combined
Contraceptives, Oral